Skip to main content
Fig. 4 | Trials

Fig. 4

From: An Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study

Fig. 4

Administration of IMP during the ILiAD trial. Randomised participants will attend site pharmacies to collect IMP as outlined. Each participant has a designated carton held at the trial pharmacies. IMP is randomly allocated as placebo or levetiracetam to arm1 and to arm 2. Participants then collect IMP from carton 1 and then carton 2 and titrate medication/placebo as per the administration schedules

Back to article page

Trials

ISSN: 1745-6215